Metabolic reprogramming networks in the gastric cancer tumor microenvironment: an integrated axis of nutrient competition, metabolic crosstalk, and immunosuppression - Report - MDSpire

Metabolic reprogramming networks in the gastric cancer tumor microenvironment: an integrated axis of nutrient competition, metabolic crosstalk, and immunosuppression

  • By

  • Xiaona He

  • Jie Liu

  • Wenjie Wang

  • July 9, 2026

  • 0 min

Share

Clinical Report: Networks of Metabolic Reprogramming in Gastric Cancer

Overview

This review elucidates the complex interactions of nutrient competition, metabolic crosstalk, and immune suppression within the tumor microenvironment (TME) of gastric cancer.

Background

Gastric cancer is a leading cause of cancer-related morbidity and mortality worldwide, with treatment options limited for advanced stages. The tumor microenvironment significantly influences therapeutic outcomes, particularly in the context of immunotherapy.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

  • The TME of gastric cancer is characterized by hypoxia, acidosis, and nutrient deficiency.
  • Intense competition for nutrients between cancer and immune cells leads to metabolic deprivation in effector T cells.
  • Accumulation of immunosuppressive metabolites such as lactic acid and adenosine actively suppresses immune function.
  • Metabolic crosstalk within the TME reshapes the immunosuppressive niche through receptor signaling and epigenetic modifications.

Clinical Implications

A comprehensive understanding of the metabolic reprogramming in gastric cancer can inform therapeutic strategies.

Conclusion

The intricate network of metabolic interactions in the TME of gastric cancer plays a role in immune evasion and treatment resistance.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Glycolytic reprogramming in cancer: immune crosstalk, nutrient competition, and supportive care perspectives
  2. Frontiers in Immunology, 2026 -- Editorial: Community Series in Tumor Microenvironment and Metabolic Reprogramming in Cancer: Volume II
  3. Frontiers in Immunology, 2026 -- Cancer Metabolism: From the Warburg Effect to Precision Therapy
  4. ASCO Publications -- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline
  5. Frontiers in Immunology — Spatial immune archetypes in gastric and colorectal cancer: a proposed conceptual framework for immunotherapy resistance and therapeutic remodeling
  6. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline | ASCO Publications
  7. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859. | Journal of Clinical Oncology
  8. Metabolites as agents and targets for cancer immunotherapy | Nature Reviews Drug Discovery

Original Source(s)

Related Content